Synta Pharmaceuticals Corp (NASDAQ:SNTA)

2.67
Delayed Data
As of Mar 05
 +0.24 / +9.88%
Today’s Change
2.18
Today|||52-Week Range
6.33
+0.75%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$264.6M

Company Description

Synta Pharmaceuticals Corp. discovers, develops and commercializes novel pharmaceutical products. It is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with cancer and other severe medical conditions. Its lead drug candidate, ganetespib, is a next generation Hsp90 inhibitor in Phase 3 development for non-small cell lung cancer and in a broad development program including clinical trials for breast cancer, ovarian cancer and acute myeloid leukemia. In addition, the company developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA.

Contact Information

Synta Pharmaceuticals Corp.
45 Hartwell Avenue
Lexington Massachusetts 02421
P:(781) 274-8200
Investor Relations:
(781) 541-7250

Employees

Shareholders

Other institutional38.34%
Individual stakeholders37.71%
Mutual fund holders12.70%

Top Executives

Anne C. WhitakerPresident, Chief Executive Officer & Director
Chen SchorChief Operating Officer & Executive Vice President
Marc R. SchneebaumChief Financial Officer & Senior Vice President
Vojo VukovicChief Medical Officer & Senior Vice President
Iman El-HariryVice President-Clinical Research

To view my watchlist

Not a member yet?

Sign up now for a free account